CJC-1295: Side Effects & Safety
Part of the CJC-1295 Complete Guide
CJC 1295 / Ipamorelin Blend (10mg)
Advertiser link — we may earn a commission at no extra cost to you.
CJC-1295 Safety: Two Different Molecules, Two Safety Profiles
'CJC-1295' refers to two distinct molecules with substantially different safety profiles. Combining them is the most common source of safety confusion in this peptide:
- CJC-1295 with DAC (Drug Affinity Complex): the original ConjuChem molecule, modified to bind albumin and produce a ~7-day half-life. The DAC version produces sustained, non-pulsatile GH and IGF-1 elevation. This is the version associated with the Phase 1/2 trials and most clinical safety data.[1]
- CJC-1295 without DAC (Modified GRF 1-29, "Mod GRF 1-29"): the same GHRH analog without the DAC component, giving a short half-life of ~30 minutes. Preserves the body's natural pulsatile GH release pattern. Generally regarded as having a better safety profile in research settings.
CJC-1295 is not on the agenda for the July 23–24, 2026 FDA Pharmacy Compounding Advisory Committee 503A bulks list meeting. CJC-1295 is not FDA-approved. See our legal status guide for current regulatory context.
Reported Side Effects by Form
| Effect | DAC form | No-DAC (Mod GRF 1-29) | Mechanism |
|---|---|---|---|
| Water retention / facial puffiness | Common | Mild, transient | GH-mediated sodium retention |
| Transient facial flushing / warmth | Common | Common (post-injection) | Histamine release / vasodilation |
| Tingling / numbness in extremities | Common at higher doses | Uncommon | Fluid effects on peripheral nerves; CTS-like |
| Injection-site reaction | Common (mild) | Common (mild) | Local immune response |
| Increased hunger | Common | Common | Indirect ghrelin pathway effects |
| Insulin resistance / elevated fasting glucose | Documented in trials at higher doses | Uncommon at standard doses | GH antagonizes insulin action |
| Joint pain / carpal-tunnel-like symptoms | Reported with sustained DAC dosing | Rare | Fluid retention in joint capsules |
| Headache | Occasional | Occasional | Variable; usually transient |
| Lipoatrophy / lipohypertrophy at injection sites | Possible with rotation failure | Possible with rotation failure | Repeated local exposure |
DAC-Specific Safety Considerations
The DAC version's ~7-day half-life produces sustained, non-pulsatile GH stimulation. This is mechanistically different from native GHRH (pulsatile) and from short-acting Mod GRF 1-29. Concerns specific to DAC use:
- GH receptor desensitization: constant GH receptor stimulation can downregulate receptors over time, reducing response.
- Sustained IGF-1 elevation: may produce supraphysiological IGF-1 levels. Long-term implications for cancer risk are theoretical but not characterized.
- Insulin resistance and hyperglycemia: documented with sustained GH elevation in trials of CJC-1295-DAC and well-known with chronic GH excess (acromegaly).
- Acromegalic-pattern side effects at higher doses: jaw growth, hand/foot soft-tissue thickening, organ enlargement — all dose- and duration-dependent. Not reported at standard research doses but theoretically possible with sustained supraphysiological dosing.
Historical note on the 2007 fatality
A death occurred in a French CJC-1295 clinical trial in 2007. The relationship to CJC-1295 was disputed and could not be conclusively established; the trial was halted. This event is sometimes cited in the research community as a reason for caution with the DAC version, though no published data linked the death definitively to the drug. The full clinical record was not made public.
Contraindications & Special Populations
- Active or recent malignancy: GH and IGF-1 are growth-promoting. Absolute contraindication during cancer treatment; discuss with oncology before any post-treatment use.
- Personal history of MEN syndromes or pituitary tumors.
- Active diabetic retinopathy: GH and IGF-1 can exacerbate retinopathy. Avoid until retinopathy is treated and stable.
- Type 2 diabetes (uncontrolled): insulin resistance from GH worsens glycemic control. Optimize diabetes management before initiation.
- Pregnancy and breastfeeding: no controlled data. Contraindicated.
- Acromegaly or active GH excess from any cause.
- Severe heart failure: fluid retention may worsen.
- Carpal tunnel syndrome: relative contraindication; may worsen.
Drug interactions
- Insulin / sulfonylureas / metformin: GH antagonizes insulin. Monitor glucose closely; doses may need adjustment.
- Glucocorticoids: additive insulin resistance.
- Other GH secretagogues (sermorelin, ipamorelin, GHRP-2/6, hexarelin): additive GH elevation. Combination requires caution.
- Levothyroxine: GH can affect peripheral T4-to-T3 conversion. Monitor thyroid function on prolonged use.
What to Do If You Experience Side Effects
- Mild water retention / puffiness: reduce dose by 25–50%. Switch from DAC to Mod GRF 1-29 if persistent.
- Numbness / tingling / wrist symptoms: stop immediately; this is the carpal tunnel pattern. Reassess after symptoms resolve. Consider lower dose or alternative peptide.
- Elevated fasting glucose: monitor with home glucometer. Reduce dose. Discontinue if glucose continues to drift up.
- Joint pain: reduce dose. If pain persists, discontinue and re-evaluate.
- Persistent injection-site nodules or lipodystrophy: rotate sites more aggressively, deeper subcutaneous depth, possible technique review (see injection guide).
- Vision changes: stop immediately and obtain ophthalmology evaluation.
See the CJC-1295 complete guide, dosage protocols, benefits and research, and CJC-1295 vs Ipamorelin.